awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35506764-68A1FAA5-5978-407B-8D1A-61D91DA302AF
Q35506764-68A1FAA5-5978-407B-8D1A-61D91DA302AF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35506764-68A1FAA5-5978-407B-8D1A-61D91DA302AF
In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.
P2860
Q35506764-68A1FAA5-5978-407B-8D1A-61D91DA302AF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35506764-68A1FAA5-5978-407B-8D1A-61D91DA302AF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f88158ec4b477f75a1e9c1d195e0427c7d2e3154
P2860
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.